Liquid Biopsy

Liquid Biopsy Market by Biomarkers (Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Sample (Blood Based, Urine Based), Type, Technology, Indication, End-User, Application - Global Forecast 2024-2030

360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the liquid biopsy market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[189 Pages Report] The Liquid Biopsy Market size was estimated at USD 1.70 billion in 2023 and expected to reach USD 2.05 billion in 2024, at a CAGR 20.39% to reach USD 6.25 billion by 2030.

Liquid Biopsy Market
To learn more about this report, request a free PDF copy

Liquid biopsy has emerged as an effective and non-invasive alternative to surgical biopsies, allowing medical professionals to provide accurate information about a tumor through a blood sample. They have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. The world observes an increase in the number of cancer patients with a huge preference for non-invasive diagnostics procedures, including liquid biopsies. The exponential potential of liquid biopsies in cancer detection has led to more research activities being conducted to amplify their usage. However, limited reimbursement offerings for the procedure and stringent regulations regarding their accuracy and usage significantly limit product adoption across hospitals. Product developers are developing a cost-effective line of liquid biopsies and introducing microarrays and next-generation sequencing technologies in these biopsies to improve their operational characteristics. The technology of liquid biopsies is still evolving, and its non-invasive nature promises to open new eras in clinical oncology.

Liquid Biopsy Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Regional Insights

The liquid biopsy market in the Americas and Europe is highly organized, with prominent market players developing advanced liquid biopsy diagnostics and substantial government assistance for cancer research. Several players have also received United States patents for their liquid biopsy technologies, creating an opportunity for growth in this medical approach. The Asia-Pacific nations, including Thailand, Malaysia, the Philippines, Australia, Indonesia, and Singapore, are expanding their healthcare sectors with significant investments to create a strengthened service associated with early cancer diagnostics. In May 2022, the Australian Cancer Research Foundation (ACRF) Child Cancer Liquid Biopsy Program launched a liquid biopsy program in Sydney, representing the cancer sampling and monitoring revolution. Governments in Asia have approved liquid biopsies considering the need to improve cancer diagnosis. In context, the China Food and Drug Administration (CFDA) approved Amoy Diagnostics' EGFR mutation liquid biopsy for use in 2018. Moreover, concerns regarding the prevalence of cancer, growing research initiatives, and the rapidly developing healthcare sector are expected to expand the need for liquid biopsy across the Middle East & Africa.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liquid Biopsy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liquid Biopsy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers.

    DXC vera has made tremendous progress in the fight against early-stage cancer thanks to their liquid biopsy platform. This pioneering technology is a simple blood test that could revolutionize cancer detection, allowing doctors to detect cancer cells earlier than ever before. Interestingly, the platform was developed through a combination of AI and Machine Learning technologies, making it significantly faster and more accurate than traditional techniques. With DXC vera's recent $10M funding, this platform is now readily available for early-stage cancer testing. Such groundbreaking initiatives are empowering healthcare professionals everywhere with the tools to detect and treat cancer more effectively. [Published On: 2023-02-01]

  • Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test.

    Liquid biopsy is an important breakthrough in the medical field, and Agilent Technologies' version of the test promises to make it more accessible. This liquid biopsy technology allows healthcare professionals to gather information from a patient's bloodstream instead of doing an invasive exam or surgery to obtain tissue samples. The advanced techniques used by Agilent Technologies mean that results will be accessible quickly, allowing physicians to better diagnose diseases, provide accurate prognosis for treatments, and reassess interventions with greater speed. Ultimately, this technology gives patients access to better care, faster diagnosis, and improved treatment options. [Published On: 2023-01-23]

  • Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research.

    Agilent Technologies Inc. recently announced that it had completed the acquisition of Avida Biomed, a developer of high-performance next-generation sequencing (NGS) target enrichment workflows for cancer research. This acquisition is intended to further enhance Agilent's presence in the liquid biopsy space and expand its portfolio of life science and diagnostics solutions. With this latest acquisition, Agilent gains the ability to develop innovative solutions to support cancer research, drug development, companion diagnostics and precision medicine applications using Avida's industry-leading NGS target enrichment to identify cancer-associated mutations from circulating tumor DNA. Agilent is committed to making advancements in this rapidly growing field with data-driven insights, patent protected methodologies and industry-leading expertise. [Published On: 2023-01-04]

Key Company Profiles

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Biocept, Inc., CellMax, Inc., Circulogene, Diacarta, Dxcover Limited, Epic Sciences, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Guardant Health, Inc., Illumina Inc., Inivata Limited by NeoGenomics, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems Inc., Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., OncoDNA, PerkinElmer, Inc., Personalis, Inc., SAGA Diagnostics AB, Strand Life Sciences Pvt. Ltd., Sysmex Corporation, and Tempus.

Market Segmentation & Coverage

This research report categorizes the Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Biomarkers
    • Cell-free DNA
    • Circulating Tumor Cells
    • Circulating Tumor DNA
    • Exosome
    • Extracellular Vesicles
  • Sample
    • Blood Based
    • Urine Based
  • Type
    • Assay Kits
    • Instruments
    • Services
  • Technology
    • Multi-gene Parallel Analysis using NGS
    • Single-gene Analysis using PCR Microarrays
  • Indication
    • Cancer Indication
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Melanoma
      • Prostate Cancer
    • Non-Cancer Indication
  • End-User
    • Academic & Research Centers
    • Clinical Diagnostic Laboratories
    • Hospitals
    • Physician’s Office Laboratories
  • Application
    • Early Cancer Screening
    • Recurrence Monitoring
    • Therapy Selection
    • Treatment Monitoring

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Liquid Biopsy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liquid Biopsy Market?
  3. What are the technology trends and regulatory frameworks in the Liquid Biopsy Market?
  4. What is the market share of the leading vendors in the Liquid Biopsy Market?
  5. Which modes and strategic moves are suitable for entering the Liquid Biopsy Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Liquid Biopsy Market, by Biomarkers
  7. Liquid Biopsy Market, by Sample
  8. Liquid Biopsy Market, by Type
  9. Liquid Biopsy Market, by Technology
  10. Liquid Biopsy Market, by Indication
  11. Liquid Biopsy Market, by End-User
  12. Liquid Biopsy Market, by Application
  13. Americas Liquid Biopsy Market
  14. Asia-Pacific Liquid Biopsy Market
  15. Europe, Middle East & Africa Liquid Biopsy Market
  16. Competitive Landscape
  17. Competitive Portfolio
  18. List of Figures [Total: 30]
  19. List of Tables [Total: 742]
  20. List of Companies Mentioned [Total: 31]
The Future of Cancer Detection: The Role of Liquid Biopsy in Expanding Cancer Research
June 15, 2023
BLOG
The Future of Cancer Detection: The Role of Liquid Biopsy in Expanding Cancer Research
Cancer is one of the most dreaded diseases that affect people worldwide. It is a challenge for both doctors and patients to detect this disease at its early stages. With more than 18 million new cases of cancer diagnosed every year globally, there is an urgent need to improve the accuracy and timeliness of cancer detection. The liquid biopsy approach represents a significant breakthrough in cancer research, and its potential to improve early detection is enormous. This blog post explores the role of liquid biopsy in expanding cancer research and the availability of funding that drives its growth.

Understanding Liquid Biopsy:
Liquid biopsy is a non-invasive procedure that uses blood, urine, cerebrospinal fluid, and other bodily fluids to identify cancer-related material. This approach can detect early signs of cancer, monitor how it progresses, and identify changes in the DNA of cancer cells. The liquid biopsy approach has revolutionized cancer research and has offered a more effective method for detecting cancer as compared to traditional tissue biopsy. Although still in the experimental stage, liquid biopsy has shown great promise in detecting and tracking cancer.

The Role of Funding in Advancing Liquid Biopsy:
The availability of funding has always been a critical factor in advancing medical research. Liquid biopsy is no exception. There has been a significant increase in funding for liquid biopsy research in recent years, which has stimulated growth in the field. This funding not only supports research projects but also improves the practical application of this technology. In addition, funding has attracted entrepreneurs to the industry, leading to new start-ups focused on the development of advanced liquid biopsy technologies.

Liquid Biopsy and Early Cancer Detection:
Early cancer detection is vital in improving cancer survival rates. Liquid biopsy can help in this area by detecting cancer earlier than other methods. Early detection improves the chances of a patient responding positively to treatment. Liquid biopsy may also help doctors pinpoint the specific type of cancer cells present, allowing them to personalize treatment to the individual patient's requirements and at the earliest stage possible.

Improved Precision in Cancer Treatment:
Cancer treatment is becoming more personalized thanks to liquid biopsy. This approach can help identify specific mutations and characteristics of individual cancer cells, which offers more precise treatment options. This method enables medical professionals to monitor how treatments are working and, when necessary, change tactics quickly to better target the cancer. This precision minimizes side effects and improves the efficacy of cancer treatment.

Challenges Facing Liquid Biopsy:
The technology behind liquid biopsy is still relatively new, and there are still several issues that must be addressed to help its wider adoption. Some of these issues include standardization of testing to improve consistency, the availability of laboratories that can conduct analysis, and regulatory approval. These challenges must be addressed to help mainstream the use of liquid biopsy in cancer patients.

Liquid biopsy represents a major breakthrough in cancer detection and treatment. This technology offers personalized treatment solutions, enables early detection, and improves cancer treatment outcomes. The availability of funding has played a significant role in advancing research in this field. This investment has helped to stimulate growth in the industry, attracting entrepreneurs and new start-ups focused on developing advanced liquid biopsy technologies. Addressing challenges that hinder the wider adoption of liquid biopsy is necessary for this technology to prove life-saving for cancer patients. Hopefully, further investment and research in this area will make it possible for liquid biopsy to become mainstream in the healthcare industry.

Frequently Asked Questions
  1. How big is the Liquid Biopsy Market?
    Ans. The Global Liquid Biopsy Market size was estimated at USD 1.70 billion in 2023 and expected to reach USD 2.05 billion in 2024.
  2. What is the Liquid Biopsy Market growth?
    Ans. The Global Liquid Biopsy Market to grow USD 6.25 billion by 2030, at a CAGR of 20.39%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.